Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%
ECONOMY & POLICY

Syngene Delivers Steady Growth in Q4 FY25; Full-Year PAT Down 8%

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. 

For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. 

Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. 

Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. 

(BSE)     

Syngene International reported a strong performance in Q4 FY25 with revenue from operations rising 11% year-on-year to Rs 10.18 billion, crossing the Rs 10 billion mark for the first time. The quarter also saw sequential revenue growth of 8%, supported by robust performance across research, development, and manufacturing services. Operating EBITDA grew 9% YoY, with a margin of 35%, while profit after tax stood at Rs 1.83 billion. For the full fiscal year, revenue from operations rose 4% to Rs 36.42 billion. However, profit after tax before exceptional items declined 8% to Rs 4.75 billion, impacted by sectoral headwinds in the first half. Adjusted for one-offs, full-year PAT remained flat with 1% YoY growth. EBITDA margin for the year moderated to 29%. Key highlights included the acquisition of a biologics manufacturing site in Baltimore, USA, enhancing Syngene’s single-use bioreactor capacity to 50KL and expanding its footprint in the US biologics CDMO market. The company also launched SYNe-MAP™, a proprietary B2B e-commerce platform to streamline biological assay services. Looking ahead, Syngene expects FY26 revenue growth in the early teens on an underlying basis, with reported growth likely in the mid-single digits due to client-level inventory balancing. EBITDA margins are expected to moderate to the mid-twenties due to costs from the new US facility. The Board has recommended a final dividend of Rs 1.25 per share for FY25. (BSE)     

Next Story
Infrastructure Urban

Reliance, Diehl Advance Pact for Precision-Guided Munitions

Diehl Defence CEO Helmut Rauch and Reliance Group’s Founder Chairman Anil D. Ambani have held discussions to advance their ongoing strategic partnership focused on Guided and Terminally Guided Munitions (TGM), under a cooperation agreement originally signed in 2019.This collaboration underscores Diehl Defence’s long-term commitment to the Indian market and its support for the Indian Government’s Make in India initiative. The partnership’s current emphasis is on the urgent supply of the Vulcano 155mm Precision Guided Munition system to the Indian Armed Forces.Simultaneously, the “Vulc..

Next Story
Infrastructure Urban

Modis Navnirman to Migrate to Main Board, Merge Subsidiary

Modis Navnirman Limited has announced that its Board of Directors has approved a key strategic initiative involving migration from the BSE SME platform to the Main Board of both BSE and NSE, alongside a merger with its wholly owned subsidiary, Shree Modis Navnirman Private Limited.The move to the main boards marks a major milestone in the company’s growth trajectory, reflecting its consistent financial performance, robust corporate governance, and long-term commitment to value creation. This transition will grant the company access to a broader investor base, improve market participation, en..

Next Story
Infrastructure Urban

Global Capital Flows Remain Subdued, EMEA Leads in Q1 2025

The Bharat InvITs Association’s industry update for Q1 2025 shows subdued global capital flows, with investment volumes remaining at the lower end of the five-year range despite a late 2024 recovery. According to data from Colliers and MSCI Real Capital Analytics, activity in North America declined slightly, while EMEA maintained steady levels and emerged as the top region for investment in standing assets.The EMEA region now hosts seven of the top ten cross-border capital destinations for standing assets, pushing the United States’ share of global activity below 15 per cent. Meanwhile, in..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?